Evolent Health Reports 31.3% Revenue Decline in Q2 2025, Net Loss of $51.1 Million

Evolent Health, Inc. reported a significant decline in financial performance for the second quarter of 2025, with total revenue decreasing by 31.3% to $444.3 million compared to $647.1 million in the same period of 2024. The decrease was primarily attributed to contractual updates with key customers, including a $130.4 million reduction from transitioning a customer from the Performance Suite to the Specialty Technology and Services Suite, and an $82.7 million decrease due to the narrowing of scope for certain Performance Suite customers. For the first half of 2025, revenue also fell by 27.9% to $928.0 million, down from $1.3 billion in the prior year.

The company's operating expenses for the second quarter totaled $445.5 million, a decrease of 30.3% from $639.4 million in the previous year. Cost of revenue dropped by 36.3% to $343.9 million, reflecting the revenue decline and a shift towards higher-margin product types. Selling, general, and administrative expenses increased by 8.7% to $75.2 million, driven by higher personnel costs. Evolent reported a net loss attributable to common shareholders of $51.1 million for the quarter, compared to a loss of $6.4 million in the same quarter of 2024.

In terms of operational metrics, Evolent's average Lives on Platform for the Performance Suite decreased to 6.5 million from 6.9 million year-over-year, while the average PMPM fee fell from $22.30 to $13.76. The company also experienced a decline in its Medicaid and Medicare revenue streams, with Medicaid revenue dropping to $193.0 million from $217.1 million and Medicare revenue falling to $109.0 million from $268.7 million.

Strategically, Evolent has been focusing on integrating its services and enhancing its technology platform. The company completed the acquisition of Machinify, a software platform leveraging artificial intelligence, for $28.5 million, which is expected to enhance its service offerings. Additionally, Evolent has entered into a Commitment Letter with Ares Capital Corporation to provide up to $150 million in non-dilutive debt capital, aimed at retiring its 2025 Convertible Notes and supporting working capital needs.

Looking ahead, Evolent anticipates continued challenges due to rising medical claims costs and regulatory uncertainties, particularly following the enactment of the One Big Beautiful Bill Act, which amends U.S. tax law. The company believes its current cash and cash equivalents, along with undrawn credit facilities, will be sufficient to meet its operational needs for the next twelve months. However, the ongoing dynamics in the healthcare market may impact its financial condition and operational results in the future.